{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
phenyl aminosalicylate
to a specific field?
Class (Stereo):
CHEMICAL (ABSOLUTE)
Lirequinil is a benzoquinolizinone derivative. It is a partial agonist to the benzodiazepine (BDZ) receptor. Lirequinil slightly lowered the rhythmic slow-wave activity frequency during waking mobility. Lirequinil acts more selectively than nitrazepam to promote the drowsy EEG pattern, and the partial agonistic properties may minimize the residual effects during waking mobility similar to the short-acting agent zopiclone. Lirequinil was well tolerated at all doses, causing no clinically relevant changes in vital signs or laboratory parameters. At doses of 10 and 30 mg there were signs of unsteady gait, indicating a central nervous system depressant effect. Lirequinil had been in phase II for the treatment of sleep disorders.
Status:
Class (Stereo):
CHEMICAL (MIXED)
Hexopyrronium is an antihistaminic agent. Its gastric antisecretory action was studied in human. Information about the current use of this drug is not available.
Status:
Investigational
Class (Stereo):
CHEMICAL (RACEMIC)
Daledalin is a norepinephrine reuptake inhibitor, developed in the 1970s by Pfizer. In animal models, daledalin potentiates the action of catecholamines, reverses the hypothermia induced by noradrenaline or noradnamine injected into the cerebral ventricles of mice. Daledalin potentiates amphetamine-induced excitation in rats and antagonizes reserpine-hypothermia in mice, tetrabenazine-sedation in rats and reserpine- and tetrabenazine-induced ptosis in mice. It inhibits noradrenaline and 5-hydroxytryptamine uptake by rat brain slices in vitro. In a clinical trial on patients with a depressive illness, no difference in efficacy between daledalin and amitriptyline was found.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Devazepide (L-364718 or MK-329) is a nonpeptide antagonist for the peripheral (type-A) cholecystokinin (CCK) receptor, which has proved effective in blocking the actions of both exogenous and endogenous CCK in several species. It is an orally active antagonist of CCK-stimulated pancreaticobiliary output in man. Devazepide has been developing for the treatment of anxiety, cancer, neuropathic pain however development discontinued.
Status:
Investigational
Source:
INN:flumetramide [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
FLUMETRAMIDE is a skeletal muscle relaxant.
Status:
Investigational
Source:
NCT00160134: Phase 2 Interventional Completed Congestive Heart Failure
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Derenofyllin (SLV320) is a selective adenosine A1 receptor antagonist, which is under investigation for the treatment of heart failure with renal dysfunction. Adverse events considered related to SLV320 were dizziness, nausea, transient hypertension and transient hypotension.
Status:
Investigational
Class (Stereo):
CHEMICAL (UNKNOWN)
ISOMAZOLE is a cardiovascular agent with both inotropic and vasodilator activities. It acts primarily as a phosphodiesterase inhibitor.
Status:
Investigational
Source:
NCT00699517: Phase 3 Interventional Completed Sarcoma
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Ombrabulin is an experimental drug candidate discovered by Ajinomoto and further developed by Sanofi-Aventis for cancer treatment.
Ombrabulin is a synthetic water-soluble analog of combretastatin A4, derived from the South African willow bush (Combretum caffrum), with potential vascular-disrupting and antineoplastic activities. Ombrabulin binds to the colchicine binding site of endothelial cell tubulin, inhibiting tubulin polymerization and inducing mitotic arrest and apoptosis in endothelial cells. As apoptotic endothelial cells detach from their substrate, tumor blood vessels collapse; the acute disruption of tumor blood flow may result in tumor necrosis. Ombrabulin has been used in trials studying the treatment of Sarcoma, Neoplasms, Solid Tumor, Neoplasms, Malignant, and Advanced Solid Tumors, among others. In January 2013, Sanofi said it discontinued development of Ombrabulin after disappointing results from phase III clinical trials.
Class (Stereo):
CHEMICAL (RACEMIC)
Solpecainol [EGIS 2936, EGYT 2936] is a sodium channel antagonist with antianginal and class I antiarrhythmic effects. It was in phase II clinical trials with Egis Pharmaceuticals for the treatment of angina pectoris and arrhythmias, but this development was discontinued.
Status:
Investigational
Source:
NCT00716144: Phase 2 Interventional Completed Psoriasis
(2006)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Targets:
Conditions:
Talarozole (formerly R115866) is a new highly potent and selective azole derivative, which inhibits cytochrome-P450-dependent all-trans-retinoic acid catabolism by blocking the cytochrome P450 enzyme isoform CYP26, a retinoic acid hydroxylase. It is in clinical development for the treatment of psoriasis and acne. However, no local pharmacokinetic data on the diffusion behaviour of talarozole in the skin itself are available. As topical application might be an interesting alternative to oral therapy because of the reduced systemic side effects. The distribution of talarozole within the skin was investigated: 80% was located in the epidermis, while the remaining 20% was found in the dermis. The epidermal concentration of talarozole achieved after a single topical application was sufficiently high to enable the potential induction of local retinoid-like effects.
